RECORD // Company

Biovie Inc.

Formerly: NANOANTIBIOTICS, INC.

Built 2026-11-22T00:04:16Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
  • BIOVIE INC. · the SEC registrant record of this company
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • BioVie Inc. · Ctgov · same registered legal name as 'BIOVIE INC.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-06 · accession 0001520138-26-000461

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-5,605,0703 months ended 2026-09-3010-Q2026-11-060001520138-26-0004612026-11-22 00:04 UTCReport an error
Interest expense$9683 months ended 2026-09-3010-Q2026-11-060001520138-26-0004612026-11-22 00:04 UTCReport an error
Cash and cash equivalents$7,732,817at 2026-09-3010-Q2026-11-060001520138-26-0004612026-11-22 00:04 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001580149
Ticker
BIVI
EIN
462510769
UEI
WF5HU3FN79L5
CUSIP
09074F504
Record ID
sx:sec:0001580149

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-22 00:04 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-19SEC EDGAR company profile2026-11-22 00:04 UTCReport an error
State of incorporationNV2026-11-19SEC EDGAR company profile2026-11-22 00:04 UTCReport an error
Fiscal year end (MMDD)06302026-11-19SEC EDGAR company profile2026-11-22 00:04 UTCReport an error
Business address680 W NYE LANE, SUITE 201, CARSON CITY, NV, 897032026-11-19SEC EDGAR company profile2026-11-22 00:04 UTCReport an error
ExchangesNasdaq, Nasdaq2026-11-19SEC EDGAR company profile2026-11-22 00:04 UTCReport an error
Net income (loss) (fiscal year ended 2026-06-30)$-22,072,8632026-06-3010-K, XBRL NetIncomeLoss2026-11-22 00:04 UTCReport an error
Total assets (at 2026-06-30)$14,250,4622026-06-3010-K, XBRL Assets2026-11-22 00:04 UTCReport an error
Stockholders' equity (at 2026-06-30)$10,270,2702026-06-3010-K, XBRL StockholdersEquity2026-11-22 00:04 UTCReport an error
Cash and cash equivalents (at 2026-06-30)$8,977,3702026-06-3010-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:04 UTCReport an error
Operating cash flow (fiscal year ended 2026-06-30)$-19,024,8062026-06-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:04 UTCReport an error
Operating lease liabilities (at 2026-06-30)$275,4302026-06-3010-K, XBRL OperatingLeaseLiability2026-11-22 00:04 UTCReport an error
Form D total offering amount (D filed 2026-11-19)$02026-11-19D2026-11-22 00:04 UTCReport an error
Form D total amount sold (D filed 2026-11-19)$02026-11-19D2026-11-22 00:04 UTCReport an error
Form D industry groupBiotechnology2026-11-19D2026-11-22 00:04 UTCReport an error
Form D revenue rangeDecline to Disclose2026-11-19D2026-11-22 00:04 UTCReport an error
Form D date of first sale2026-11-032026-11-19D2026-11-22 00:04 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-11-10)On November 10, 2026, BioVie Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). On September 21, 2026, the record date for stockholders entitled to notice of, and to vote at, the Annual Meeting, 8,682,710 shares of the Company’s Class A common stock (“Common Stock”) were outstanding. The holders of 4,749,367 shares of Common Stock were present at the Annual Meeting, either virtually or represented by proxy, constituting a quorum. The following matters were considered at the Annual Meeting and the final voting results are set forth below: Proposal 1. Election of Directors Stockholders elected all of the Company’s nominees for director to hold office…2026-11-10SEC EDGAR 8-K 0001520138-26-000471 (text as filed, excerpt)2026-11-22 00:04 UTCReport an error
8-K Item 1.01, Entry Into a Material Definitive Agreement (filed 2026-11-06)On November 3, 2026, BioVie Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Direct Offering”), (i) 960,000 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $1.60 per Share, and (ii) in lieu of Shares, 2,002,500 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,002,500 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an offering price of $1.5999 per Pre-Funded Warrant, which…2026-11-06SEC EDGAR 8-K 0001520138-26-000460 (text as filed, excerpt)2026-11-22 00:04 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-11-06)The information contained above in Item 1.01 related to the Private Placement is hereby incorporated by reference into this Item 3.02. Item 7.01 Regulation FD Disclosure. On November 3, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by…2026-11-06SEC EDGAR 8-K 0001520138-26-000460 (text as filed, excerpt)2026-11-22 00:04 UTCReport an error
8-K Item 1.01, Entry Into a Material Definitive Agreement (filed 2026-09-14)On September 11, 2026, BioVie Inc., a Nevada corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell from time to time, to or through the Agent, shares of the Company’s Class A common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $6,464,341 (the “Placement Shares”). The Placement Shares will be offered and sold pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-296924) (the “Registration Statement”), which was filed with the Securities and Exchange Commission (“SEC”) on June 18, 2026 and…2026-09-14SEC EDGAR 8-K 0001520138-26-000391 (text as filed, excerpt)2026-11-22 00:04 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-06)On August 6, 2026, BioVie Inc. (the “Company”) issued a press release announcing results from the Company’s Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as…2026-08-06SEC EDGAR 8-K 0001520138-26-000312 (text as filed, excerpt)2026-11-22 00:04 UTCReport an error
Largest institutional holder #1 (13F as filed): Diametric Capital, LP$497,8732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #2 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$248,1612026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #3 (13F as filed): CITADEL ADVISORS LLC$186,1472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$137,5582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #5 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$137,2572026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD FIDUCIARY TRUST CO$72,8612026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #7 (13F as filed): JANE STREET GROUP, LLC$69,5692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #8 (13F as filed): PRELUDE CAPITAL MANAGEMENT, LLC$63,2112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #9 (13F as filed): NORTHERN TRUST CORP$42,3312026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Largest institutional holder #10 (13F as filed): Persistent Asset Partners Ltd$29,0922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:04 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$02026-09-30USAspending recipient profile2026-11-22 00:04 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)12026-09-30USAspending recipient profile2026-11-22 00:04 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.